Methods of using RAD51 inhibitors for treatment of pancreatic cancer
US-12064419-B2 · Aug 20, 2024 · US
Small molecule RNase inhibitors and methods of use
US9693999B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9693999-B2 |
| Application number | US-201514933804-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 5, 2015 |
| Priority date | Jan 26, 2011 |
| Publication date | Jul 4, 2017 |
| Grant date | Jul 4, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a Gram positive bacterial infection in a subject, comprising administering to the subject: an effective amount of an RNase inhibitor of the following structure: or a pharmaceutically acceptable salt or prodrug thereof; and an antibacterial compound. 2. The method of claim 1 , wherein the bacterial infection is a Staphylococcus infection. 3. The method of claim 1 , wherein the bacterial infection is a Staphylococcus aureus infection. 4. The method of claim 3 , wherein the Staphylococcus aureus infection is a drug-resistant Staphylococcus aureus infection. 5. The method of claim 3 , wherein the Staphylococcus aureus infection is a biofilm-associated Staphylococcus aureus infection. 6. The method of claim 1 , wherein the RNase inhibitor is an RnpA inhibitor. 7. The method of claim 1 , wherein the antibacterial compound is selected from the group consisting of astromicin, biapenem, ciprofloxacin, clinafloxacin, clindamycin, daptomycin, dihydrostreptomycin, enoxacin, fleroxacin, gentamicin, imipenem, kanamycin, linezolid, lomefloxacin, meropenem, neomycin, norfloxacin, ofloxacin, pefloxacin, piperacillin, quinupristin, sparfloxacin, spectinomycin, streptomycin, sulopenem, temafloxacin, ticarcillin, tobramycin, tosufloxacin, vancomycin, and virginiamycin.
Assignees
Inventors
Classifications
Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
1-aryl substituted, e.g. piretanide · CPC title
Ribonucleases (RNAses); Deoxyribonucleases (DNAses) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9693999B2 cover?
- Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.
- Who is the assignee on this patent?
- Univ Rochester, Univ Nebraska, Temple University—Of the Commonwealth System of Higher Education
- What technology area does this patent fall under?
- Primary CPC classification A61K31/427. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).